

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**

BEST AVAILABLE COPY



The Patent Office



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP9 1RH

JC649 U.S. PRO
09/326020
06/04/99

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.


In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed An Brewster

Dated 11 May 1999

THIS PAGE BLANK (USPTO)

**Request for grant of a patent**

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road

Newport

Gwent NP9 1RH

1. Your reference

PA 439

2. Patent application number

(The Patent Office will fill in this part)

05 JUN 1998

9812088.4

3. Full name, address and postcode of the or of each applicant (underline all surnames)

CELLTECH THERAPEUTICS LIMITED
216 BATH ROAD
SLOUGH
SL1 4EN

Patents ADP number (if you know it)

— 6672877001 of

UK

4. Title of the invention

CHEMICAL COMPOUNDS

5. Name of your agent (if you have one)

PATENTS DEPARTMENT
CELLTECH THERAPEUTICS LIMITED
216 BATH ROAD
SLOUGH
SL1 4EN

Patents ADP number (if you know it)

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

See note (d))

YES

9. Enter the number of sheets for any of the following items you are filing with this form.
 Do not count copies of the same document

Continuation sheets of this form	<input type="radio"/>
Description	<input checked="" type="radio"/>
Claim(s)	<input type="radio"/>
Abstract	<input type="radio"/>
Drawing(s)	<input type="radio"/>

10. If you are also filing any of the following, state how many against each item.

Priority documents	<input type="radio"/>
Translations of priority documents	<input type="radio"/>
Statement of inventorship and right to grant of a patent (Patents Form 7/77)	<input type="radio"/>
Request for preliminary examination and search (Patents Form 9/77)	<input type="radio"/>
Request for substantive examination (Patents Form 10/77)	<input type="radio"/>
Any other documents (please specify)	<input type="radio"/>

11.

I/We request the grant of a patent on the basis of this application.

For AND ON BEHALF OF CELLTECH THERAPEUTICS LIMITED
 Signature  Date 5th June 1998

12. Name and daytime telephone number of person to contact in the United Kingdom

Dr. P. Ansell 01753 534655

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) For details of the fee and ways to pay please contact the Patent Office.

CHEMICAL COMPOUNDS

5 This invention relates to a series of phenylalanine derivatives, to compositions containing them, to processes for their preparation, and to their use in medicine.

10 Over the last few years it has become increasingly clear that the physical interaction of inflammatory leukocytes with each other and other cells of the body plays an important role in regulating immune and inflammatory responses [Springer, T A. *Nature*, 346, 425, (1990); Springer, T. A. *Cell* 76, 301, (1994)]. Many of these interactions are mediated by specific cell surface molecules collectively referred to as cell adhesion molecules.

15 The adhesion molecules have been sub-divided into different groups on the basis of their structure. One family of adhesion molecules which is believed to play a particularly important role in regulating immune and inflammatory responses is the integrin family. This family of cell surface glycoproteins has a typical non-covalently linked heterodimer structure. At 20 least 14 different integrin alpha chains and 8 different integrin beta chains have been identified [Sonnenberg, A. *Current Topics in Microbiology and Immunology*, 184, 7, (1993)]. The members of the family are typically named according to their heterodimer composition although trivial nomenclature is widespread in this field. Thus the integrin termed $\alpha_4\beta_1$ 25 consists of the integrin alpha 4 chain associated with the integrin beta 1 chain, but is also widely referred to as Very Late Antigen 4 or VLA4. Not all of the potential pairings of integrin alpha and beta chains have yet been observed in nature and the integrin family has been subdivided into a number of subgroups based on the pairings that have been recognised 30 [Sonnenberg, A. *ibid*].

35 The importance of cell adhesion molecules in human leukocyte function has been further highlighted by a genetic deficiency disease called Leukocyte Adhesion Deficiency (LAD) in which one of the families of leukocyte integrins is not expressed [Marlin, S. D. *et al* *J. Exp. Med.* 164, 855 (1986)]. Patients with this disease have a reduced ability to recruit

leukocytes to inflammatory sites and suffer recurrent infections which in extreme cases may be fatal.

5 The potential to modify adhesion molecule function in such a way as to beneficially modulate immune and inflammatory responses has been extensively investigated in animal models using specific monoclonal antibodies that block various functions of these molecules [e.g. Issekutz, T. B. J. Immunol. 3394, (1992); Li, Z. *et al* Am. J. Physiol. 263, L723, (1992); Binns, R. M. *et al* J. Immunol. 157, 4094, (1996)]. A number of 10 monoclonal antibodies which block adhesion molecule function are currently being investigated for their therapeutic potential in human disease.

15 One particular integrin subgroup of interest involves the $\alpha 4$ chain which can pair with two different beta chains $\beta 1$ and $\beta 7$ [Sonnenberg, A. *ibid*]. The $\alpha 4\beta 1$ pairing occurs on many circulating leukocytes (for example lymphocytes, monocytes and eosinophils) although it is absent or only present at low levels on circulating neutrophils. $\alpha 4\beta 1$ binds to an adhesion molecule (Vascular Cell Adhesion Molecule-1 also known as VCAM-1) 20 frequently up-regulated on endothelial cells at sites of inflammation [Osborne, L. Cell, 62, 3, (1990)]. The molecule has also been shown to bind to at least three sites in the matrix molecule fibronectin [Humphries, M. J. *et al*. Ciba Foundation Symposium, 189, 177, (1995)]. Based on data obtained with monoclonal antibodies in animal models it is believed 25 that the interaction between $\alpha 4\beta 1$ and ligands on other cells and the extracellular matrix plays an important role in leukocyte migration and activation [Yednock, T. A. *et al*, Nature, 356, 63, (1992); Podolsky, D. K. *et al*. J. Clin. Invest. 92, 373, (1993); Abraham, W. M. *et al*. J. Clin. Invest. 93, 776, (1994)].

30 The integrin generated by the pairing of $\alpha 4$ and $\beta 7$ has been termed LPAM-1 [Holzmann, B and Weissman, I. EMBO J. 8, 1735, (1989)] and like $\alpha 4\beta 1$, binds to VCAM-1 and fibronectin. In addition, $\alpha 4\beta 7$ binds to an adhesion molecule believed to be involved in the homing of leukocytes to 35 mucosal tissue termed MAdCAM-1 [Berlin, C. *et al*, Cell, 74, 185, (1993)]. The interaction between $\alpha 4\beta 7$ and MAdCAM-1 may also be important at


sites of inflammation outside of mucosal tissue [Yang, X-D. *et al*, PNAS, 91, 12604 (1994)].

Regions of the peptide sequence recognised by $\alpha_4\beta_1$ and $\alpha_4\beta_7$ when they bind to their ligands have been identified. $\alpha_4\beta_1$ seems to recognise LDV, IDA or REDV peptide sequences in fibronectin and a QIDSP sequence in VCAM-1 [Humphries, M. J. *et al*, *ibid*] whilst $\alpha_4\beta_7$ recognises a LDT sequence in MAdCAM-1 [Briskin, M. J. *et al*, *J. Immunol.* 156, 719, (1996)]. There have been several reports of inhibitors of these interactions being designed from modifications of these short peptide sequences [Cardarelli, P. M. *et al* *J. Biol. Chem.* 269, 18668, (1994); Shroff, H. N. *Bioorganic. Med. Chem. Lett.* 6, 2495, (1996); Vanderslice, P. J. *Immunol.* 158, 1710, (1997)]. It has also been reported that a short peptide sequence derived from the $\alpha_4\beta_1$ binding site in fibronectin can inhibit a contact hypersensitivity reaction in a trinitrochlorobenzene sensitised mouse [Ferguson, T. A. *et al*, *PNAS* 88, 8072, (1991)].

Since the alpha 4 subgroup of integrins are predominantly expressed on leukocytes inhibition of their ligand binding functions can be expected to be beneficial in a number of immune or inflammatory disease states. However, because of the ubiquitous distribution and wide range of functions performed by other members of the integrin family it is very important to be able to identify selective inhibitors of the alpha 4 subgroup.

We have now found a group of compounds which are potent and selective inhibitors of the binding of α_4 integrins to their ligands. Members of the group are able to inhibit the binding of α_4 integrins such as $\alpha_4\beta_1$ and/or $\alpha_4\beta_7$ to their ligands at concentrations at which they generally have no or minimal inhibitory action on α integrins of other subgroups. The compounds are thus of use in medicine, for example in the prophylaxis and treatment of immune or inflammatory disorders as described hereinafter.

Thus according to one aspect of the invention we provide a compound of formula (1)



wherein

R is a carboxylic acid (CO_2H) or a derivative thereof;

5 R^1 is a hydrogen atom or a hydroxyl, straight or branched alkoxy or optionally substituted cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group;

10 Alk^1 is an optionally substituted aliphatic or heteroaliphatic chain;

L^1 is a linker atom or group;

r and s, which may be the same or different, is each zero or an integer 1 provided that when r is zero R^1 is an optionally substituted cycloaliphatic, polycycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group;

15 Alk^2 is a straight or branched alkylene chain;

m is zero or an integer 1;

20 R^2 is a hydrogen atom or a methyl group;

R^3 is a hydrogen atom or a straight or branched alkyl group;

25 R^4 is an optionally substituted aliphatic or cycloaliphatic group; and the salts, solvates, hydrates and N-oxides thereof, for use in modulating cell adhesion.

The compounds of formula (1) are potent and selective inhibitors of the binding of $\alpha 4$ integrins to their ligands. The ability of the compounds to act in this way may be simply determined by employing tests such as those described in the Examples hereinafter. In particular compounds of the invention are advantageously selective $\alpha_4\beta_1$ inhibitors.

The compounds of formula (1) are thus of use in modulating cell adhesion and in particular are of use in the prophylaxis and treatment of diseases or disorders involving inflammation in which the extravasation of leukocytes plays a role. The invention extends to such a use and to the use of compounds of formula (1) for the manufacture of a medicament for treating such diseases or disorders. Diseases or disorders of this type include

inflammatory arthritis such as rheumatoid arthritis vasculitis or polydermatomyositis, multiple sclerosis, allograft rejection, diabetes, inflammatory dermatoses such as psoriasis or dermatitis, asthma and inflammatory bowel disease.

5

For the prophylaxis or treatment of disease the compounds of formula (1) may be administered as pharmaceutical compositions, and according to a further aspect of the invention we provide a pharmaceutical composition which comprises a compound of formula (1) together with one or more pharmaceutically acceptable carriers, excipients or diluents, for use in modulating cell adhesion, particularly in the prophylaxis and treatment of diseases or disorders involving inflammation as just described.

10

15 Pharmaceutical compositions for use according to the invention may take a form suitable for oral, buccal, parenteral, nasal, topical or rectal administration, or a form suitable for administration by inhalation or insufflation and the invention extends to the use of a compound of formula (1) in the manufacture of such formulations.

20 For oral administration, the pharmaceutical compositions may take the form of, for example, tablets, lozenges or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium glycollate); or wetting agents (e.g. sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents, emulsifying agents, non-aqueous vehicles and preservatives. The preparations may also contain buffer salts, flavouring, colouring and sweetening agents as appropriate.

25

30

35

Preparations for oral administration may be suitably formulated to give controlled release of the active compound.

For buccal administration the compositions may take the form of tablets or

5 lozenges formulated in conventional manner.

The compounds for formula (1) may be formulated for parenteral administration by injection e.g. by bolus injection or infusion. Formulations for injection may be presented in unit dosage form, e.g. in glass ampoule

10 or multi dose containers, e.g. glass vials. The compositions for injection may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising, preserving and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable

15 vehicle, e.g. sterile pyrogen-free water, before use.

In addition to the formulations described above, the compounds of formula (1) may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation or by intramuscular

20 injection.

For nasal administration or administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation for pressurised packs or a nebuliser,

25 with the use of suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas or mixture of gases.


The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack or dispensing device may be accompanied by instructions for administration.

The quantity of a compound of formula (1) required for the prophylaxis or

35 treatment of a particular condition will vary depending on the compound chosen, and the condition of the patient to be treated. In general,

however, effective daily dosages may range from around 100ng/kg to 100mg/kg e.g. around 0.01mg/kg to 40mg/kg body weight for oral or buccal administration, from around 10ng/kg to 50mg/kg body weight for parenteral administration and around 0.05mg to around 1000mg e.g. 5 around 0.5mg to around 1000mg for nasal administration or administration by inhalation or insufflation.

Particular compounds of formula (1) form a further feature of the invention and in a further aspect we therefore provide a compound of formula (1a):
10



wherein

R is a carboxylic acid (-CO₂H) or a derivative thereof;
15 R¹ is an optionally substituted cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, polyheterocyclaliphatic, aromatic or heteroaromatic group;
Alk¹ is an optionally substituted aliphatic or heteroaliphatic chain;
L¹ is a linker atom or group;
20 r and s, which may be the same or different, is each zero or an integer 1;
Alk² is a straight or branched alkylene chain;
m is zero or an integer 1;
R² is a hydrogen atom or a methyl group;
R³ is a hydrogen atom or a straight or branched alkyl group;
25 R⁴ is an optionally substituted aliphatic or cycloaliphatic group;
and the salts, solvates, hydrates and N-oxides thereof.

It will be appreciated that compounds of formulae (1) and (1a) may have one or more chiral centres. Where one or more chiral centres is present,
30 enantiomers or diastereomers may exist, and the invention is to be understood to extend to all such enantiomers, diasteromers and mixtures thereof, including racemates. Formulae (1) and (1a) and the formulae

hereinafter are intended to represent all individual isomers and mixtures thereof, unless stated or shown otherwise.

5 In the compounds of formulae (1) and (1a), derivatives of the carboxylic acid group R include carboxylic acid esters and amides. Particular esters and amides include those $\text{-CO}_2\text{R}^{5a}$ and $\text{-CON}(\text{R}^{5a})_2$ groups described below.

10 When in the compounds of formulae (1) and (1a) L^1 is present as a linker atom or group it may be any divalent linking atom or group. Particular examples include -O- or -S- atoms or -C(O)- , -C(O)O- , -C(S)- , -S(O)- , -S(O)_2 , $\text{-N}(\text{R}^5)\text{-}$ [where R^5 is a hydrogen atom or a straight or branched alkyl group], $\text{-CON}(\text{R}^5)\text{-}$, $\text{-OC(O)N}(\text{R}^5)\text{-}$, $\text{-CSN}(\text{R}^5)\text{-}$, $\text{-N}(\text{R}^5)\text{CO-}$, $\text{-N}(\text{R}^5)\text{C(O)O-}$, $\text{-N}(\text{R}^5)\text{CS-}$, $\text{-S(O)N}(\text{R}^5)\text{-}$, $\text{-S(O)}_2\text{N}(\text{R}^5)\text{-}$, $\text{-N}(\text{R}^5)\text{S(O)-}$, $\text{-N}(\text{R}^5)\text{S(O)}_2$, $\text{-N}(\text{R}^5)\text{CON}(\text{R}^5)\text{-}$, $\text{-N}(\text{R}^5)\text{CSN}(\text{R}^5)\text{-}$, $\text{-N}(\text{R}^5)\text{SON}(\text{R}^5)\text{-}$ or $\text{-N}(\text{R}^5)\text{SO}_2\text{N}(\text{R}^5)\text{-}$ groups. Where the linker group contains two R^5 substituents, these may be the same or different.

20 Alk^2 in the compounds of formulae (1) and (1a) may be for example a straight or branched C_{1-3} alkylene chain. Particular examples include $\text{-CH}_2\text{-}$, $\text{-CH(CH}_3\text{)-}$, $\text{-C(CH}_3\text{)}_2\text{-}$ and $\text{-(CH}_2\text{)}_2\text{-}$.

25 When R^3 and/or R^5 in the compounds of formula (1) is a straight or branched alkyl group it may be a straight or branched C_{1-6} alkyl group, e.g. a C_{1-3} alkyl group such as a methyl or ethyl group.

30 When Alk^1 in compounds of formula (1) is an optionally substituted aliphatic chain it may be an optionally substituted C_{1-10} aliphatic chain. Particular examples include optionally substituted straight or branched C_{1-6} alkylene, C_{2-6} alkenylene, or C_{2-6} alkynylene chains.

35 Heteroaliphatic chains represented by Alk^1 include the aliphatic chains just described but with each chain additionally containing one, two, three or four heteroatoms or heteroatom-containing groups. Particular heteroatoms or groups include atoms or groups L^2 where L^2 is as defined above for L^1 when L^1 is a linker atom or group. Each L^2 atom or group

may interrupt the aliphatic chain, or may be positioned at its terminal carbon atom to connect the chain to the atom or group R¹.

Particular examples of aliphatic chains represented by Alk¹ include

5 optionally substituted -CH₂-, -CH₂CH₂-, -CH(CH₃)-, -C(CH₃)₂-,
 -(CH₂)₂CH₂-, -CH(CH₃)CH₂-, -(CH₂)₃CH₂-, -CH(CH₃)CH₂CH₂-,
 -CH₂CH(CH₃)CH₂-, -C(CH₃)₂CH₂-, -(CH₂)₄CH₂-, -(CH₂)₅CH₂-, -CHCH-,
 -CHCHCH₂-, -CH₂CHCH-, -CHCHCH₂CH₂-, -CH₂CHCHCH₂-,
 -(CH₂)₂CHCH-, -CC-, -CCCH₂-, -CH₂CC-, -CCCH₂CH₂-, -CH₂CCCH₂-,
 10 or -(CH₂)₂CC- chains. Where appropriate each of said chains may be
 optionally interrupted by one or two atoms and/or groups L² to form an
 optionally substituted heteroaliphatic chain. Particular examples include
 optionally substituted -L²CH₂-, -CH₂L²CH₂-, -L²(CH₂)₂-, -CH₂L²(CH₂)₂-,
 -(CH₂)₂L²CH₂-, -L²(CH₂)₃- and -(CH₂)₂L²(CH₂)₂- chains.

15 The optional substituents which may be present on aliphatic or heteroaliphatic chains represented by Alk¹ include one, two, three or more substituents selected from halogen atoms, e.g. fluorine, chlorine, bromine or iodine atoms, or hydroxyl, C₁-6alkoxy, e.g. methoxy or ethoxy, thiol, C₁-6alkylthio e.g. methylthio or ethylthio, amino or substituted amino groups. Substituted amino groups include -NHR⁵ and -N(R⁵)₂ groups where R⁵ is a straight or branched alkyl group as defined above. Where two R⁵ groups are present these may be the same or different. Particular examples of substituted chains represented by Alk¹ include those specific chains just described substituted by one, two, or three halogen atoms such as fluorine atoms, for example chains of the type -CH(CF₃)-, -C(CF₃)₂-
 20 -CH₂CH(CF₃)-, -CH₂C(CF₃)₂-, -CH(CF₃)₂- and -C(CF₃)₂CH₂.

25 Alkoxy groups represented by R¹ in compounds of formula (1) include straight or branched C₁-6alkoxy groups such as methoxy and ethoxy groups.

30 When R¹ is present in compounds of formulae (1) and (1a) as an optionally substituted cycloaliphatic group it may be an optionally substituted C₃-10 cycloaliphatic group. Particular examples include

optionally substituted C_{3-10} cycloalkyl, e.g. C_{3-7} cycloalkyl, or C_{3-10} cycloalkenyl e.g. C_{3-7} cycloalkenyl groups.

5 Optionally substituted heterocycloaliphatic groups represented by R^1 include the optionally substituted cycloaliphatic groups just described for R^1 but with each group additionally containing one, two, three or four heteroatoms or heteroatom-containing groups L^2 as just defined.

10 Optionally substituted polycycloaliphatic groups represented by R^1 include optionally substituted C_{7-10} bi- or tricycloalkyl or C_{7-10} bi- or tricycloalkenyl groups. Optionally substituted polyheterocycloaliphatic groups represented by R^1 include the optionally substituted polycycloalkyl groups just described, but with each group additionally containing one, two, three or four L^2 atoms or groups.

15 Particular examples of R^1 cycloaliphatic, polycycloaliphatic, heterocycloaliphatic and polyheterocycloaliphatic groups include optionally substituted cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 2-cyclobuten-1-yl, 2-cyclopenten-1-yl, 3-cyclopenten-1-yl, adamantyl, norbornyl, norbornenyl, pyrroline, e.g. 2- or 3-pyrrolinyl, pyrrolidinyl, pyrrolidinone, oxazolidinyl, oxazolidinone, dioxolanyl, e.g. 1,3-dioxolanyl, imidazolinyl, e.g. 2-imidazolinyl, imidazolidinyl, pyrazolinyl, e.g. 2-pyrazolinyl, pyrazolidinyl, thiazolinyl, thiazolidinyl, pyranyl, e.g. 2- or 4-pyranyl, piperidinyl, piperidinone, 1,4-dioxanyl, morpholinyl, morpholinone, 1,4-dithianyl, thiomorpholinyl, piperazinyl, 1,3,5-trithianyl, oxazinyl, e.g. 2H-1,3-, 6H-1,3-, 6H-1,2-, 2H-1,2- or 4H-1,4- oxazinyl, 1,2,5-oxathiazinyl, isoxazinyl, e.g. o- or p-isoxazinyl, oxathiazinyl, e.g. 1,2,5 or 1,2,6-oxathiazinyl, or oxadiazinyl e.g. 1,3,5-oxodiazinyl groups.

20 The optional substituents which may be present on the R^1 cycloaliphatic, polycycloaliphatic, heterocycloaliphatic or polyheterocycloaliphatic groups include one, two, three or more substituents represented by R^6 , each R^6 substituent being selected from halogen atoms, e.g. fluorine, chlorine, bromine or iodine atoms, or C_{1-6} alkyl, e.g. methyl or ethyl, halo C_{1-6} alkyl, e.g. halomethyl or haloethyl such as difluoromethyl or trifluoromethyl, optionally substituted by hydroxyl, e.g. $-C(OH)(CF_3)_2$, C_{1-6} alkoxy, e.g.

25

30

35

methoxy or ethoxy, haloC₁₋₆alkoxy, e.g. halomethoxy or haloethoxy such as difluoromethoxy or trifluoromethoxy, thiol, C₁₋₆alkylthio e.g. methylthio or ethylthio, or -(Alk)_vR⁷ groups in which Alk is a straight or branched C₁₋₃alkylene chain, v is zero or an integer 1 and R⁷ is a -OH, -SH, -N(R^{5a})₂,

5 -CN, -CO₂R^{5a}, -NO₂, -CON(R^{5a})₂, -CSN(R^{5a})₂, -COR^{5a}, -CSN(R^{5a})₂, -N(R^{5a})COR^{5a}, -N(R^{5a})CSR^{5a}, -SO₂N(R^{5a})₂, -N(R^{5a})SO₂R^{5a}, -N(R^{5a})CON(R^{5a})₂, -N(R^{5a})CSN(R^{5a}) or -N(R^{5a})SO₂N(R^{5a})₂ group in which R^{5a} is an atom or group as defined herein for R⁵.

10 In the compounds of formulae (1) and (1a), optionally substituted aromatic groups represented by the group R¹ include for example monocyclic or bicyclic fused ring C₆₋₁₂ aromatic groups, such as phenyl, 1- or 2-naphthyl, 1- or 2-tetrahydronaphthyl, indanyl or indenyl groups, optionally substituted by one, two, three or more R⁶ atoms or groups as just described for R¹

15 cycloaliphatic groups.

20 Optionally substituted heteroaromatic groups, represented by the group R¹ in compounds of formulae (1) and (1a) include for example optionally substituted C₁₋₉ heteroaromatic groups containing for example one, two, three or four heteroatoms selected from oxygen, sulphur or nitrogen atoms. In general, the heteroaromatic groups may be for example monocyclic or bicyclic fused ring heteroaromatic groups. Monocyclic heteroaromatic groups include for example five- or six-membered heteroaromatic groups containing one, two, three or four heteroatoms

25 selected from oxygen, sulphur or nitrogen atoms. Bicyclic heteroaromatic groups include for example nine- to thirteen-membered fused-ring heteroaromatic groups containing one, two or more heteroatoms selected from oxygen, sulphur or nitrogen atoms.

30 Particular examples of heteroaromatic groups of these types include optionally substituted pyrrolyl, furyl, thienyl, imidazolyl, N-C₁₋₆aimidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,3,4-thiadiazole, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, 1,3,5-triazinyl, 1,2,4-triazinyl, 1,2,3-triazinyl, benzofuryl, [2,3-dihydro]-benzofuryl, benzothienyl, benzotriazolyl, indolyl, isoindolyl, benzimidazolyl,

35

imidazo[1,2-a]pyridyl, benzothiazolyl, benzoxazolyl, benzopyranyl, [3,4-dihydro]benzopyranyl, quinazolinyl, naphthyridinyl, pyrido[3,4-b]pyridyl, pyrido[3,2-b]pyridyl, pyrido[4,3-b]pyridyl, quinolinyl, isoquinolinyl, tetrazolyl, 5,6,7,8-tetrahydroquinolinyl, 5,6,7,8-tetrahydroisoquinolinyl, and imidyl,

5 e.g. succinimidyl, phthalimidyl, or naphthalimidyl such as 1,8-naphthalimidyl.

Optional substituents which may be present on R¹ heteroaromatic groups include one, two, three or more R⁶ atoms or groups as described above 10 for R¹ cycloaliphatic groups.

Particular aliphatic groups represented by R⁴ in compounds of formulae (1) and (1a) include optionally substituted C₁-10aliphatic groups. Particular examples include optionally substituted straight or branched C₁-6alkyl, C₂-6alkenyl or C₂-6alkynyl groups. Optional substituents include one, two or 15 three substituents, where each substituent may be the same or different and is selected from halogen atoms, e.g. fluorine, chlorine, bromine or iodine atoms, or hydroxyl, C₁-6alkoxy, e.g. methoxy or ethoxy, thiol, C₁-6alkylthio, e.g. methylthio or ethylthio, haloC₁-6alkoxy, e.g. fluoroC₁-6alkoxy 20 such as difluoromethoxy or trifluoromethoxy, -N(R^{5b})₂ [where R^{5b} is as defined above for R⁵], C₃-7cycloalkyl, C₃-7cycloalkenyl, C₃-7cycloalkoxy or C₃-7cycloalkenoxy groups.

Particular examples of R⁴ aliphatic groups include optionally substituted 25 -CH₃, -CH₂CH₃, -CH(CH₃)₂, -(CH₂)₂CH₃, -(CH₂)₃CH₃, -CH(CH₃)CH₂CH₃, -CH₂CH(CH₃)₂, -CH(CH₃)₃, -(CH₂)₄CH₃, -(CH₂)₅CH₃, -CHCH₂, -CHCHCH₃, -CH₂CHCH₂, -CHCHCH₂CH₃, -CH₂CHCHCH₃, -(CH₂)₂CHCH₂, -CH₂CCCH₃ or -(CH₂)₂CCH groups.

30 When the group R⁴ in compounds of formula (1) or (1a) is an optionally substituted cycloaliphatic group it may be for example an optionally substituted C₃-7cycloaliphatic group. Particular examples include optionally substituted C₃-10cycloalkyl, e.g. C₃-7cycloalkyl, and C₃-10cycloalkenyl, e.g. C₃-7cycloalkenyl groups. Optional substituents include one, two or three 35 substituents, where each substituent may be the same or different and is selected from halogen atoms, e.g. fluorine, chlorine, bromine or iodine

atoms, or hydroxyl, C₁₋₆alkoxy e.g. methoxy or ethoxy, thiol, C₁₋₆alkylthio, e.g. methylthio or ethylthio, C₁₋₆alkyl, e.g. methyl or ethyl, haloC₁₋₆alkyl e.g. fluoroC₁₋₆alkyl such as difluoromethyl or trifluoromethyl, haloC₁₋₆alkoxy, e.g. fluoroC₁₋₆alkoxy such as difluoromethoxy or trifluoromethoxy or -N(R^{5b})₂ groups.

Particular examples of R⁴ cycloaliphatic groups include optionally substituted cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 2-cyclobuten-1-yl, 2-cyclopenten-1-yl and 3-cyclopenten-1-yl groups.

10 The presence of certain substituents in the compounds of formula (1) may enable salts of the compounds to be formed. Suitable salts include pharmaceutically acceptable salts, for example acid addition salts derived from inorganic or organic acids, and salts derived from inorganic and 15 organic bases.

20 Acid addition salts include hydrochlorides, hydrobromides, hydroiodides, alkylsulphonates, e.g. methanesulphonates, ethanesulphonates, or isothionates, arylsulphonates, e.g. p-toluenesulphonates, besylates or napsylates, phosphates, sulphates, hydrogen sulphates, acetates, trifluoroacetates, propionates, citrates, maleates, fumarates, malonates, succinates, lactates, oxalates, tartrates and benzoates.

25 Salts derived from inorganic or organic bases include alkali metal salts such as sodium or potassium salts, alkaline earth metal salts such as magnesium or calcium salts, and organic amine salts such as morpholine, piperidine, dimethylamine or diethylamine salts.

30 Particularly useful salts of compounds according to the invention include pharmaceutically acceptable salts, especially acid addition pharmaceutically acceptable salts.

When present, the aliphatic chain represented by Alk¹ in compounds of the invention is preferably a -CH₂- chain.

Alk² in compounds of formula (1) is preferably a -CH₂- chain and m is preferably an integer 1.

R² in compounds of formula (1) is preferably a hydrogen atom.

5

R³ in compounds of the invention is preferably a hydrogen atom.

In general in compounds of the invention -(Alk¹)_r(L¹)_s- is preferably -CH₂O- or -CON(R⁵)-.


10

In general in compounds of the invention the group R¹ is preferably an optionally substituted aromatic or heteroaromatic group. Particularly useful groups of these types include optionally substituted phenyl, pyridyl or pyrimidinyl groups, particularly those in which the substituent when present is an atom or group R⁶ as described above.

15

A particularly useful class of compounds according to the invention has the formula (1b)

20



25


wherein -W- is -CH= or -N=, each R⁶ group may be the same or different and is as generally defined above, and Alk¹, r, L¹, s and R⁴ are as generally defined above, and the salts, solvates, hydrates and N-oxides thereof.

In compounds of formula (1b) -(Alk¹)_r(L¹)_r- is preferably a -CH₂O or -CON(R⁵)- group.

R^4 in compounds according to the invention is preferably and optionally substituted straight or branched C₁-6alkyl group or an optionally substituted C₃-7cycloalkyl group.

5 The compounds of formulae (1) and (1a) may be prepared by a number of processes as generally described below and more specifically in the Examples hereinafter. In the following process description, the symbols R¹-R⁴, L¹, Alk¹, Alk², m, r, s and R when used in the formulae depicted are to be understood to represent those groups described above in relation
 10 to formula (1) unless otherwise indicated. In the reactions described below, it may be necessary to protect reactive functional groups, for example hydroxy, amino, thio or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups may be used in accordance with standard
 15 practice [see, for example, Green, T. W. in "Protective Groups in Organic Synthesis", John Wiley and Sons, 1991]. In some instances, deprotection may be the final step in the synthesis of the desired compound and the processes described hereinafter are to be understood to extend to such removal of protecting groups. For convenience, the processes described
 20 below all refer to the preparation of a compound of formula (1) but clearly the description applies equally to the preparation of compounds of formula (1a).

25 Thus a compound of formula (1) in which R is a -CO₂H group may be obtained by hydrolysis of an ester of formula (2):




where R^a is an alkyl group.

30 The hydrolysis may be performed using either an acid or a base depending on the nature of R^a, for example an organic acid such as trifluoracetic acid or an inorganic base such as lithium hydroxide optionally

in an aqueous organic solvent such as an amide, e.g. a substituted amide such as dimethylformamide, an ether, e.g. a cyclic ether such as tetrahydrofuran or dioxane or an alcohol, e.g. methanol at around ambient temperature. Where desired, mixtures of such solvents may be used.

5

Esters of formula (2) may be prepared by coupling an amine of formula (3):



10 (where R^a is as just described) or a salt thereof with an acid of formula (4):



or an active derivative thereof.

15

Active derivatives of acids of formula (4) include anhydrides, esters and halides. Particular esters include pentafluorophenyl or succinyl esters.

20 The coupling reaction may be performed using standard conditions for reactions of this type. Thus for example the reaction may be carried out in a solvent, for example an inert organic solvent such as an amide, e.g. a substituted amide such as dimethylformamide, an ether, e.g. a cyclic ether such as tetrahydrofuran, or a halogenated hydrocarbon, such as dichloromethane, at a low temperature, e.g. around -30°C to around 25 ambient temperature, optionally in the presence of a base, e.g. an organic base such as an amine, e.g. triethylamine, pyridine, or dimethylaminopyridine, or a cyclic amine, such as N-methylmorpholine.

30 Where an acid of formula (4) is used, the reaction may additionally be performed in the presence of a condensing agent, for example a diimide such as 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide or N,N'-dicyclohexylcarbodiimide, advantageously in the presence of a catalyst such as a

N-hydroxy compound e.g. a N-hydroxytriazole such as 1-hydroxybenzotriazole. Alternatively, the acid may be reacted with a chloroformate, for example ethylchloroformate, prior to reaction with the amine of formula (3).

5

Intermediates of formulae (2), (3) and (4), or compounds of formula (1), may be manipulated to introduce substituents to aromatic or heteroaromatic groups or modify existing substituents in groups of these types. Typically, such manipulation may involve standard substitution

10 approaches employing for example alkylation, arylation, heteroarylation, acylation, thioacetylation, halogenation, sulphonylation, nitration, formylation or coupling reactions. Alternatively, existing substituents may be modified for example by oxidation, reduction or cleavage reactions. Particular examples of such reactions are given below.

15

Thus in one example, a compound wherein $R^1(Alk^1)_r(L^1)_s$ is a $-L^1H$ group may be alkylated, arylated or heteroarylated using a reagent $R^1(Alk^1)_rX$ in which R^1 is other than a hydrogen atom and X is a leaving atom or group such as a halogen atom, e.g. a fluorine, bromine, iodine or chlorine atom 20 or a sulphonyloxy group such as an alkylsulphonyloxy, e.g. trifluoromethylsulphonyloxy or arylsulphonyloxy, e.g. p-toluenesulphonyloxy group.

The reaction may be carried out in the presence of a base such as a carbonate, e.g. caesium or potassium carbonate, an alkoxide, e.g. 25 potassium t-butoxide, or a hydride, e.g. sodium hydride, in a dipolar aprotic solvent such as an amide, e.g. a substituted amide such as dimethylformamide or an ether, e.g. a cyclic ether such as tetrahydrofuran.

30 In another example, a compound where $R^1(Alk^1)_r(L^1)_s$ is a $-L^1H$ group is a hydrogen atom may be functionalised by acylation or thioacetylation, for example by reaction with a reagent $R^1(Alk^1)_rL^1X$ [wherein L^1 is a $-C(O)-$, $C(S)-$, $-N(R^4)C(O)-$ or $N(R^4)C(S)-$ group], in the presence of a base, such as a hydride, e.g. sodium hydride or an amine, e.g. triethylamine or N-methylmorpholine, in a solvent such as a halogenated hydrocarbon, e.g. dichloromethane or carbon tetrachloride or an amide, e.g.

dimethylformamide, at for example ambient temperature, or by reaction with $R^1(Alk^1)_rCO_2H$, $R^1(Alk)_4COSH$ or an activated derivative thereof, for example as described above for the preparation of esters of formula (2).

- 5 In a further example a compound may be obtained by sulphonylation of a compound where $R^1(Alk^1)_r(L^1)_s$ is an -OH group by reaction with a reagent $R^1(Alk^1)_rL^1Hal$ [in which L^1 is -S(O)- or -SO₂- and Hal is a halogen atom such as chlorine atom] in the presence of a base, for example an inorganic base such as sodium hydride in a solvent such as an amide, e.g. a substituted amide such as dimethylformamide at for example ambient temperature.

- 10 In another example, a compound where $R^1(Alk^1)_r(L^1)_s$ is a -L¹H group, may be coupled with a reagent R^1OH (where R^1 is other than a hydrogen atom) or R^1Alk^1OH in a solvent such as tetrahydrofuran in the presence of a phosphine, e.g. triphenylphosphine and an activator such as diethyl, diisopropyl- or dimethylazodicarboxylate to yield a compound containing a $R^1(Alk^1)_rO-$ group.

- 15 20 In a further example, ester groups -CO₂R⁴ or -CO₂Alk⁴ in compounds of formula (1) may be converted to the corresponding acid [-CO₂H] by acid- or base-catalysed hydrolysis depending on the nature of the group R⁴ or Alk⁴. Acid- or base-catalysed hydrolysis may be achieved for example by treatment with an organic or inorganic acid, e.g. trifluoroacetic acid in an aqueous solvent or a mineral acid such as hydrochloric acid in a solvent such as dioxan or an alkali metal hydroxide, e.g. lithium hydroxide in an aqueous alcohol, e.g. aqueous methanol.

- 25 30 In a second example, -OR⁷ [where R⁷ represents an alkyl group such as methyl group] groups in compounds of formula (1) may be cleaved to the corresponding alcohol -OH by reaction with boron tribromide in a solvent such as a halogenated hydrocarbon, e.g. dichloromethane at a low temperature, e.g. around -78°C.
- 35 35 Alcohol [-OH] groups may also be obtained by hydrogenation of a corresponding -OCH₂R⁷ group (where R⁷ is an aryl group) using a metal

catalyst, for example palladium on a support such as carbon in a solvent such as ethanol in the presence of ammonium formate, cyclohexadiene or hydrogen, from around ambient to the reflux temperature. In another example, -OH groups may be generated from the corresponding ester [-CO₂Alk⁴ or CO₂R⁴] or aldehyde [-CHO] by reduction, using for example a

5 complex metal hydride such as lithium aluminium hydride or sodium borohydride in a solvent such as methanol.

In another example, alcohol -OH groups in compounds of formula (1) may

10 be converted to a corresponding -OR³ group by coupling with a reagent R⁷OH in a solvent such as tetrahydrofuran in the presence of a phosphine, e.g. triphenylphosphine and an activator such as diethyl-, diisopropyl-, or dimethylazodicarboxylate.

15 Aminosulphonylamino [-NHSO₂NH₂] groups in compounds of formula (1) may be obtained, in another example, by reaction of a corresponding amine [-NH₂] with sulphamide in the presence of an organic base such as pyridine at an elevated temperature, e.g. the reflux temperature.

20 In a further example amine (-NH₂) groups may be alkylated using a reductive alkylation process employing an aldehyde and a borohydride, for example sodium triacetoxyborohydride or sodium cyanoborohydride, in a solvent such as a halogenated hydrocarbon, e.g. dichloromethane, a ketone such as acetone, or an alcohol, e.g. ethanol, where necessary in
25 the presence of an acid such as acetic acid at around ambient temperature.

In a further example, amine [-NH₂] groups in compounds of formula (1) may be obtained by hydrolysis from a corresponding imide by reaction with
30 hydrazine in a solvent such as an alcohol, e.g. ethanol at ambient temperature.

In another example, a nitro [-NO₂] group may be reduced to an amine [-NH₂], for example by catalytic hydrogenation using for example hydrogen
35 in the presence of a metal catalyst, for example palladium on a support such as carbon in a solvent such as an ether, e.g. tetrahydrofuran or an

alcohol e.g. methanol, or by chemical reduction using for example a metal, e.g. tin or iron, in the presence of an acid such as hydrochloric acid.

Aromatic halogen substituents in compounds of the invention may be

5 subjected to halogen-metal exchange with a base, for example a lithium base such as n-butyl or t-butyl lithium, optionally at a low temperature, e.g. around -78°C, in a solvent such as tetrahydrofuran and then quenched with an electrophile to introduce a desired substituent. Thus, for example, a formyl group may be introduced by using dimethylformamide as the

10 electrophile; a thiomethyl group may be introduced by using dimethyldisulphide as the electrophile.

In another example, sulphur atoms in compounds of the invention, for example when present in the linker group L¹ may be oxidised to the

15 corresponding sulphoxide using an oxidising agent such as a peroxy acid, e.g. 3-chloroperoxybenzoic acid, in an inert solvent such as a halogenated hydrocarbon, e.g. dichloromethane, at around ambient temperature.

Intermediates of formulae (3) and (4), R¹(Alk¹)_rX, R¹(Alk¹)_rL¹X,

20 R¹(Alk¹)_rCO₂H, R¹OH and R¹Alk¹OH are either known compounds or may be prepared from known starting materials by use of analogous processes to those used for the preparation of the known compounds and/or by treating known compounds by one or more of the alkylation, acylation and other manipulations described herein.

25 N-oxides of compounds of formula (1) may be prepared for example by oxidation of the corresponding nitrogen base using an oxidising agent such as hydrogen peroxide in the presence of an acid such as acetic acid, at an elevated temperature, for example around 70°C to 80°C, or alternatively

30 by reaction with a peracid such as peracetic acid in a solvent, e.g. dichloromethane, at ambient temperature.

35 Salts of compounds of formula (1) may be prepared by reaction of a compound of formula (1) with an appropriate base in a suitable solvent or mixture of solvents e.g. an organic solvent such as an ether e.g. diethylether, or an alcohol, e.g. ethanol using conventional procedures.

Where it is desired to obtain a particular enantiomer of a compound of formula (1) this may be produced from a corresponding mixture of enantiomers using any suitable conventional procedure for resolving 5 enantiomers.

Thus for example diastereomeric derivatives, e.g. salts, may be produced by reaction of a mixture of enantiomers of formula (1) e.g. a racemate, and an appropriate chiral compound, e.g. a chiral base. The diastereomers 10 may then be separated by any convenient means, for example by crystallisation and the desired enantiomer recovered, e.g. by treatment with an acid in the instance where the diastereomer is a salt.

In another resolution process a racemate of formula (1) may be separated 15 using chiral High Performance Liquid Chromatography. Alternatively, if desired a particular enantiomer may be obtained by using an appropriate chiral intermediate in one of the processes described above.

The following Examples illustrate the invention. All temperatures are in 20 °C. The following abbreviations are used:

EDC - 1-(3-dimethylaminopropyl)3-ethycarbodiimide;
DMF - dimethylformamide; HOBT - 1-hydroxybenzotriazole;
NMM - N-methylmorpholine; Boc - tert-butoxycarbonyl;

25 **INTERMEDIATE 1** used in the following Example is (N-3,5-dichloro-4-picoloyl)-*L*-4-aminophenylalanine methyl ester prepared from 3,5-dichloro-4-picoloyl chloride and *N*-Boc-*L*-4-aminophenylalanine methyl ester.

30 **EXAMPLE 1**

N-Isopropaloyl-(N'3,5-dichloro-4-picoloyl)-*L*-4-aminophenylalanine methyl ester

Intermediate 1, hydrochloride salt (1.24mmol) in DMF (10ml) was treated successively with NMM (1.1 equivalents, 1.37mmol), isopropaloyl chloride 35 (1.1 equivalents, 1.37mmol) and a catalytic amount of 4-dimethylamino-pyridine. The reaction was stirred at 20° for 16h and evaporated to

dryness. The residue was partitioned between 50% sodium hydrogen carbonate and ethyl acetate and the organics washed with 10% citric acid, brine and dried ($MgSO_4$). Evaporation gave the title compound as a white solid. Yield 50%. 1H NMR $[(CD_3)_2SO]$ δ H 10.85 (1H, s), 8.78 (2H, s), 8.15 (1H, d, J 8.0Hz), 7.55 (2H, d, J 8.5Hz), 7.22 (2H, d, J 8.5Hz), 4.45 (1H, m), 3.62 (3H, s), 3.01 (1H, dd, J 13.8, 5.4Hz), 2.88 (1H, dd, J 13.8, 9.4Hz), 2.39 (1H, quint, J 6.8Hz), 0.96 (3H, d, J 6.8Hz) and 0.90 (3H, d, J 6.8Hz). m/z (ES+ 60V) 462, 460 (MNa^+ , 12, 22%), 440, 438 (MH^+ , 71, 100%).

10 The following compounds of Examples 2 and 3 were prepared in a similar manner:

EXAMPLE 2

N-Cyclopropaloyl-(N'-3,5-dichloro-4-picoloyl)-L-4-aminophenylalanine methyl ester

15 from Intermediate 1, hydrochloride salt and cyclopropanecarbonyl chloride. Yield 45%. 1H NMR $[(CD_3)_2SO]$ δ H 10.87 (1H, s), 8.79 (2H, s), 8.51 (1H, d, J 7.8Hz), 7.57 (2H, d, J 8.5Hz), 7.23 (2H, d, J 8.5Hz), 4.48 (1H, m), 3.62 (3H, s), 3.00 (1H, dd, J 13.8, 5.7Hz), 2.89 (1H, dd, J 13.8, 8.9Hz), 1.62 (1H, m) and 0.63 (4H, m). m/z (ES+ 60V) 460, 458 (MNa^+ , 15, 25%), 438, 436 (MH^+ , 63, 100%).

EXAMPLE 3

N-Pivaloyl-(N'-3,5-dichloro-4-picoloyl)-L-4-aminophenylalanine methyl ester

25 from Intermediate 1, hydrochloride salt and pivaloyl chloride. Yield 44%. 1H NMR $[(CD_3)_2SO]$ δ H 10.8 (1H, s), 8.79 (2H, s), 7.71 (1H, d, J 8.0Hz), 7.55 (2H, d, J 8.2Hz), 7.23 (2H, d, J 8.5Hz), 4.44 (1H, m), 3.63 (3H, s), 3.06 (1H, dd, J 13.6, 5.4Hz), 2.97 (1H, dd, J 13.6, 9.6Hz) and 1.04 (9H, s). 30 m/z (ES+ 160V) 476, 474 (MNa^+ , 6, 10%), 454, 452 (MH^+ , 60, 100%).

EXAMPLE 4

N-Isopropaloyl-(N'-3,5-dichloro-4-picoloyl)-L-4-aminophenylalanine.

35 A solution of the compound of Example 1 (0.5mmol) in tetrahydrofuran (8ml) and water (6ml) was treated with lithium hydroxide dihydrate (1.5 equivalents, 0.75mmol) and stirred for 4h at 20°. The reaction was

adjusted to pH2 with 2M hydrochloric acid and evaporated to dryness. Trituration of the residue with water gave the title compound as a white solid. Yield 90%. m.p. 257-258°. ^1H NMR $[(\text{CD}_3)_2\text{SO}]$ δH 8.79 (2H, s), 8.00 (1H, d, J 8.1Hz), 7.55 (2H, d, J 8.5Hz), 7.23 (2H, d, J 8.5Hz), 4.40 (1H, m), 3.03 (1H, dd, J 13.7, 4.9Hz), 2.86 (1H, dd, J 13.7, 9.4Hz), 2.39 (1H, quint, J 6.8Hz), 0.95 (3H, d, J 6.8Hz) and 0.89 (3H, d, J 6.8Hz). m/z (ES+, 60V) 448, 446 (MNa $^+$, 9, 13%), 426, 424 (MH $^+$, 66, 100%).

10 The following compounds of Examples 5 and 6 were prepared in a similar manner:

EXAMPLE 5

N-Cyclopropaloyl-(N'-3,5-dichloro-4-picloyl)-L-4-aminophenylalanine from the compound of Example 2. Yield 78%. m.p. 248-250°. ^1H NMR $[(\text{CD}_3)_2\text{SO}]$ δH 8.79 (2H, s), 8.36 (1H, d, J 8.1Hz), 7.56 (2H, d, J 8.5Hz), 7.24 (2H, d, J 8.5Hz), 4.43 (1H, m), 3.02 (1H, dd, J 13.8, 52Hz) 2.86 (1H, dd, J 13.8, 9.1Hz) and 1.63 (1H, m). m/z (ES+, 60V), 446, 444 (MNa $^+$, 13, 24%), 424, 422 (MH $^+$, 66, 100%).

20 EXAMPLE 6

N-Pivaloyl-(N'-3,5-dichloro-4-picloyl)-L-4-aminophenylalanine from the compound of Example 3 Yield 88%. m.p. 125-128°. ^1H NMR $[(\text{CD}_3)_2\text{SO}]$ δH 10.83 (1H, s), 8.78 (2H, s), 7.53 (3H, m), 7.23 (2H, d, J 8.5Hz), 4.40 (1H, m), 3.06 (1H, dd, J 13.7, 4.7Hz), 2.96 (1H, dd, J 13.6, 9.8Hz) and 1.03 (9H, s). m/z (ES+, 160V) 462, 460 (MNa $^+$, 16, 25%), 440, 438 (MH $^+$, 65, 100%).

EXAMPLE 7

N-Acetyl-(N'-3,5-dichloro-4-picloyl)-L-4-aminophenylalanine methyl ester A mixture of Intermediate 1, hydrochloride salt (1.24mmol), HOBT (1.1 equivalents, 1.36mmol), NMM (2.2 equivalents, 0.3ml) and glacial acetic acid (1.05 equivalents, 74 μ l) were stirred together in DMF(10ml) during the addition of EDC (1.1 equivalents, 1.36mmol) and then for 16h at 20°. The reaction was evaporated and partitioned between ethyl acetate and sodium hydrogen carbonate. The organic phase was washed

successively with 10% citric acid (x 2), sodium hydrogen carbonate (x 1) and brine (x 1) and dried (MgSO_4). Evaporation gave the title compound as a pale lemon foam in 94% yield. $^1\text{HNMR}$ $[(\text{CD}_3)_2\text{SO}]$ δH 10.01 (1H, s), 8.47 (2H, s), 7.54 (2H, d, \downarrow 8.5Hz), 7.01 (2H, d, \downarrow 8.5Hz), 6.47 (1H, d, \downarrow 7.9Hz), 4.75 (1H, m), 3.64 (3H, s), 2.99 (2H, m) and 1.90 (3H, s). m/z (ES+, 160V) 434, 432 (M Na^+ , 38, 54%), 410 (M H^+ , 69, 100%).

EXAMPLE 8

N-Acetyl-(N'-3,5-dichloro-4-picoloyl)-L-4-aminophenylalanine

10 A solution of the compound of Example 7 (1.1mmol) in tetrahydrofuran (15ml) and water (12ml) was treated with lithium hydroxide (1.5 equivalents, 1.65mmol) and stirred for 16h at 20°. The reaction was adjusted to pH2 with 2M hydrochloric acid and evaporated down to a yellow oil. Trituration with water gave the title compound as an off-white solid in 65% yield. m.p. 198-202°. $^1\text{HNMR}$ $[(\text{CD}_3)_2\text{SO}]$ δH 10.85 (1H, s), 8.78 (2H, s), 8.15 (1H, d, \downarrow 8.0Hz), 7.55 (2H, d, \downarrow 8.5Hz), 7.22 (2H, d, \downarrow 8.5Hz), 4.39 (1H, m), 3.00 (1H, dd, \downarrow 13.8, 5.0Hz) and 2.82 (1H, dd, \downarrow 13.8, 9.3Hz). m/z (ES+, 160V), 420, 418 (M Na^+ , 6.9%), 398, 396 (M H^+ , 47, 100%).

20 The following assays can be used to demonstrate the potency and selectivity of the compounds according to the invention. In each of these assays an IC₅₀ value was determined for each test compound and represents the concentration of compound necessary to achieve 50% inhibition of cell adhesion where 100% = adhesion assessed in the absence of the test compound and 0% = absorbance in wells that did not receive cells.

$\alpha_4\beta_1$ Integrin-dependent Jurkat cell adhesion to VCAM-Ig

30 96 well NUNC plates were coated with F(ab)₂ fragment goat anti-human IgG Fc γ -specific antibody [Jackson Immuno Research 109-006-098: 100 μl at 2 $\mu\text{g/ml}$ in 0.1M NaHCO₃, pH 8.4], overnight at 4°. The plates were washed (3x) in phosphate-buffered saline (PBS) and then blocked for 1h in PBS/1% BSA at room temperature on a rocking platform. After washing 35 (3x in PBS) 9 ng/ml of purified 2d VCAM-Ig diluted in PBS/1% BSA was

added and the plates left for 60 minutes at room temperature on a rocking platform. The plates were washed (3x in PBS) and the assay then performed at 37° for 30 min in a total volume of 200 μ l containing 2.5×10^5 Jurkat cells in the presence or absence of titrated test compounds.

5

Each plate was washed (2x) with medium and the adherent cells were fixed with 100 μ l methanol for 10 minutes followed by another wash. 100 μ l 0.25% Rose Bengal (Sigma R4507) in PBS was added for 5 minutes at room temperature and the plates washed (3x) in PBS. 100 μ l 50% (v/v) ethanol in PBS was added and the plates left for 60min after which the absorbance (570nm) was measured.

10

$\alpha_4\beta_7$ Integrin-dependent JY cell adhesion to MAdCAM-Ig

This assay was performed in the same manner as the $\alpha_4\beta_1$ assay except that MAdCAM-Ig (150ng/ml) was used in place of 2d VCAM-Ig and a sub-line of the β -lympho blastoid cell-line JY was used in place of Jurkat cells. The IC₅₀ value for each test compound was determined as described in the $\alpha_4\beta_1$ integrin assay.

20

$\alpha_5\beta_1$ Integrin-dependent K562 cell adhesion to fibronectin

96 well tissue culture plates were coated with human plasma fibronectin (Sigma F0895) at 5 μ g/ml in phosphate-buffered saline (PBS) for 2 hr at 37°C. The plates were washed (3x in PBS) and then blocked for 1h in 100 μ l PBS/1% BSA at room temperature on a rocking platform. The blocked plates were washed (3x in PBS) and the assay then performed at 37°C in a total volume of 200 μ l containing 2.5×10^5 K562 cells, phorbol-12-myristate-13-acetate at 10ng/ml, and in the presence or absence of titrated test compounds. Incubation time was 30 minutes. Each plate was fixed and stained as described in the $\alpha_4\beta_1$ assay above.

30

$\alpha_m\beta_2$ -dependent human polymorphonuclear neutrophils adhesion to plastic

96 well tissue culture plates were coated with RPMI 1640/10% FCS for 2h at 37°C. 2×10^5 freshly isolated human venous polymorphonuclear

neutrophils (PMN) were added to the wells in a total volume of 200 μ l in the presence of 10ng/ml phorbol-12-myristate-13-acetate, and in the presence or absence of test compounds, and incubated for 20min at 37°C followed by 30min at room temperature. The plates were washed in medium and

5 100 μ l 0.1% (w/v) HMB (hexadecyl trimethyl ammonium bromide, Sigma H5882) in 0.05M potassium phosphate buffer, pH 6.0 added to each well. The plates were then left on a rocker at room temperature for 60 min. Endogenous peroxidase activity was then assessed using tetramethyl benzidine (TMB) as follows: PMN lysate samples mixed with 0.22% H₂O₂

10 (Sigma) and 50 μ g/ml TMB (Boehringer Mannheim) in 0.1M sodium acetate/citrate buffer, pH 6.0 and absorbance measured at 630nm.

α IIb/ β 3 -dependent human platelet aggregation

Human platelet aggregation was assessed using impedance aggregation on the Chronolog Whole Blood Lumiaggregometer. Human platelet-rich plasma (PRP) was obtained by spinning fresh human venous blood anticoagulated with 0.38% (v/v) tri-sodium citrate at 220xg for 10 min and diluted to a cell density of 6 x 10⁸/ml in autologous plasma. Cuvettes contained equal volumes of PRP and filtered Tyrode's buffer (g/liter: NaCl 8.0; MgCl₂.H₂O 0.427; CaCl₂ 0.2; KCl 0.2; D-glucose 1.0; NaHCO₃ 1.0; NaHPO₄.2H₂O 0.065). Aggregation was monitored following addition of 2.5 μ M ADP (Sigma) in the presence or absence of inhibitors.

In the above assays the compounds of the invention generally have IC₅₀ values in the α 4 β 1 and α 4 β 7 assays of 1 μ M and below. The compounds of the Examples typically had IC₅₀ values of 100nM and below in these assays and demonstrated selective inhibition of α 4 β 1. In the other assays featuring α integrins of other subgroups the same compounds had IC₅₀ values of 50 μ M and above thus demonstrating the potency and selectivity

25 30 of their action against α 4 integrins.